ACI-7104 — Full data
H2 2026
Full week-100 results from Part 1 of VacSYn trial expected in H2 2026Source filing
ACIU biotech catalysts & pipeline
AC IMMUNE SA · Data as of 2026-09-08
Upcoming catalysts
ACI-19764 — Initial data
Late 2026
Dosing of patients with cardiovascular risk factors has commenced in a Phase 1 b portion of the trial with initial results on inhibition of inflammation as measured by hsCRP reduction expected around year end ;Source filing
ACI-19764 — Full data
H1 2027
Full results from the Phase 1/1b trial are expected in H1 2027Source filing